

FIG. 1





FIG. 2



3/18

FIG. 3A

1C1 competes for Hp binding to Neat-1





FIG. 3B

2F4 competes for Hp with Neat-2















FIG. 5



6/18

FIG. 6





8/18

FIG. 8





FIG. 9A


Kidney Distribution



USA300 1.65e8


FIG. 9B

Kidney Distribution



USA300 2.05e8


FIG. 10
Inhibition of ClfA



	23D6	27H4	11H10
IC50 (µg/ml)	1.916	4.801	0.8713

11/18

FIG. 11



12/18

FIG. 12






FIG. 13



Challenge dose: 2.98e7 cfu

FIG. 14



Challenge dose: 2.89e7 cfu

Figure 15




Figure 16

LC10/11H10 Combo effect on IV lethal challenge
with CA-MRSA USA300 (strain SF8300, 6.4e7 cfu/mouse)





Figure 17


LC10/11H10 Combo effect on IV lethal challenge
with HA-MRSA USA100 (strain NRS382, 9.2e7 cfu/mouse)



p value: Log Rank (mantel-cox) test

Figure 18

LC10/11H10 Combo effect on IV lethal challenge
with HA-MSSA USA200 (strain NRS261, 1.18e8 cfu/mouse)



p value: Log Rank (mantel-cox) test